Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of trifluridine/tipiracil with or without ramucirumab in previously treated advanced gastric or esophagogastric junction cancer
jRCTs041220120Phase 2Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing FTD/TPI monotherapy with FTD/TPI plus ramucirumab (2 arms). Primary endpoint: Progression-free survival. Started Jan 2023; status: active, not recruiting.
02
Drugs
trifluridine + tipiracilramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs041220120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220120.